Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Med Sci. 2013 Oct 31;9(5):936-43. doi: 10.5114/aoms.2013.34991. Epub 2013 Apr 30.

The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus.

Author information

  • 1Department of Medicine and Nutrition, Division of Health Sciences, University of Guanajuato, México.

Abstract

Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide, presenting a great challenge to the public health systems due to high morbidity and mortality, because of frequent micro-/macro-vascular complications. Many treatment options are now available, with different efficacy as well as mechanisms of action to improve deranged glucose metabolism. We review some of the available data on derivatives of meglitinide, namely nateglinide and repaglinide. These two compounds increase insulin secretion by a mechanism similar to the one of sulfonylureas, but with a shorter half-life. Nateglinide and repaglinide, derivatives of meglitinides, have characteristic pharmacodynamic and pharmacokinetic properties that, together with their proposed mechanism of action, make them useful for type 2 diabetes mellitus, especially when used in combination therapy.

KEYWORDS:

glycemic control; hypoglycemia; meglitinide; nateglinide; post-prandial glucose excursion; repaglinide

PMID:
24273582
[PubMed]
PMCID:
PMC3832818
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk